TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Allergy Therapeutics ( (GB:AGY) ) has provided an update.
Allergy Therapeutics has issued 13 new ordinary shares to finance the purchase and cancellation of 9,848,333 deferred shares, in line with shareholder-approved repurchase terms. This move has not affected the company’s ordinary shares in issue or the total voting rights, which remain at 4,766,439,951.
More about Allergy Therapeutics
Allergy Therapeutics is a fully integrated commercial biotechnology company specializing in allergy vaccines, focusing on developing treatments to address common allergies.
YTD Price Performance: 18.46%
Average Trading Volume: 523,094
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £367.1M
See more data about AGY stock on TipRanks’ Stock Analysis page.